 |
|
| HENRY TSAI , M.D. |
| |
| |
Office: |
Desert Cancer Care, Inc.
39700 Bob Hope Drive,
Bob Hope Classic Medical Bldg,
Suite 108, Rancho Mirage, CA 92270 |
 |
| |
|
Affiliating Institutions : |
Eisenhower Medical Center
39000 Bob Hope Dr.,
Rancho Mirage, CA 92270
John F. Kennedy Hospital
47-111 Monroe Street
Indio, CA 92201
|
|
| |
Education: |
|
| |
MD:
1997-2001
|
Medical School
Wayne State University School of Medicine
Detroit, Michigan |
| |
2001-2004 |
Internal Medicine Internship & Residency
Emory University
Atlanta, Georgia |
| |
Fellowship:
2004-2007 |
Hematology & Medical Oncology Fellowship
Emory University
Winship Cancer Institute |
| |
Board Certification: |
Internal Medicine |
| |
|
Medical Oncology |
| |
|
Hematology |
| |
Interests: |
Particular interest in Gastrointestinal Malignancies |
| |
Positions and Appointments: |
|
| |
2010 - Current |
Desert Cancer Center, Inc.
Uihlein Bldg, #201
Eisenhower Medical Center Campus
39000 Bob Hope Drive
Rancho Mirage, CA 92270 |
| |
2007 - 2010 |
Antelope Valley Cancer Center
44105 N 15th Street West 207
Lancaster, CA 93534 |
| |
Licenses: |
California
Georgia |
| |
Manuscript Reviewer : |
|
| |
2005 - present |
Reviews on Recent Clinical Trials |
| |
Workshops and Symposiums : |
|
| |
7/2005 |
AACR Aspen, Colorado, Molecular Biology in Clinical Oncology Workshop |
| |
1/2006 |
ASCO Gastrointestinal Symposium, San Francisco |
| |
7/2006 |
ASCO/AACR Vail, Colorado, Methods in Clinical Cancer Research Workshop |
| |
Presentations/Abstracts : |
|
| |
2003 |
AACR Toronto, Canada. "Regulation of APC induced T-Cell Proliferation is dependant upon Responding T-Cell Populations and can be inhibited by co-culture in memory T-Cells." Abstract number 101053. |
| |
2004 |
American College of Gastroenterology, Orlando, Florida. "Epstein-Barr Induced Hepatitis: An Evolving Cause of Cholestasis." |
| |
2004 |
AMA Residents and Fellow Section, Atlanta, Georgia. "Migratory pain, Hypohydrosis, and Renal Failure." Case Report. |
| |
2006 |
ASCO Atlanta, Georgia. "Increased Cytoplasmic Localization of KLF5 in Prostate Cancer." |
| |
Honors and Awards: |
|
| |
1989 |
LAMP Optimist Club Service Award |
| |
1990 |
University of California, Berkeley Honors |
| |
1995 |
Boston University, Honors |
| |
1997 |
Wayne State University, Schopol of Medicine, Honors |
| |
Teaching: |
|
| |
2005-2006 |
Emroy University Monthly Medical Resident Lectures |
| |
2005-2006 |
Course Coordnator in Cancer Biology for Hermatology/Oncology Fellows |
| |
Lectures: |
|
| |
09/05/2007 |
"Anticoagulations for Elective Surgery" CME talk for Lancaster Community Hospital |
| |
03/2008 |
"Breast Cancer" Lancaster/Palmdale Community Talk |
| |
05/07/2008 |
"The VEGF Pathway As A Therapeutic Target in Cancer" CME Talk for LCH |
| |
03/21/2009 |
"Cardiac Toxicity of Cancer Drugs" CME Antelope Valley Hospital |
| |
06/18/2009 |
"Von Willebrand Disease" CME Antelope Valley Hospital ED |
| |
2008- |
Tumor Board Chairman for Antelope Valley Hospital, Monthly tumor board |
| |
Consultant: |
|
| |
Lilly, Pfizer, Novartis |
|
| |
Grand Rounds: |
|
| |
2/2005 |
Emory University Medicine Grand Rounds: Fabry's Disease |
| |
12/2005 |
Emory University Winship Cancer Institute Grand Rounds: Gene Therapy in Prostate Cancer and Novel Clinical Trial Design |
| |
MDS Observation Registry |
|
| |
NSABP B-44-I Beth trial: Bevacizumab with Trastuzumab Adjuvant Therapy in Her2+ Breast Cancer . A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with Her-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Tratuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
Other ongoing Trials with UCLA, Pfizer |
